Soleno Therapeutics Stock Surges 47% on FDA Approval, Trading Volume Drops to 234th Rank

On March 28, 2025, Soleno Therapeutics (SLNO) experienced a significant surge in its stock price, rising by 6.83% over the past two days, with a cumulative increase of 47.01%. The trading volume for the day was $363 million, marking a 65.02% decrease from the previous day, placing it at the 234th position in the daily stock market rankings.

Soleno Therapeutics' stock price soared following the FDA's approval of Vykat XR (diazoxide choline) for treating hyperphagia in Prader-Willi syndrome (PWS) patients. This approval has generated substantial investor confidence, leading to a notable increase in the company's stock value.

Analysts are optimistic about the revenue potential of Vykat XR, particularly due to its clean label without warnings, which allows for higher pricing. Piper Sandler has maintained a $93 price target for the stock, reflecting the market's positive outlook. The average target price for Soleno Therapeutics, based on the estimates of nine analysts, is $93.11, with a high estimate of $123.00 and a low estimate of $70.00. This average target implies an upside of 31.67% from the current price.

Stifel has raised its stock target for Soleno Therapeutics to $108 following the FDA approval, indicating a strong bullish sentiment among analysts. The consensus recommendation from nine brokerage firms is currently 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy and 5 denotes a Sell.

Soleno Therapeutics' stock has seen a significant surge in trading volume, reaching $103.8 million on March 27, 2025, marking a 555.05% increase from the previous day. This surge in trading volume reflects the growing investor interest and confidence in the company following the FDA approval of Vykat XR.